3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neuroblastoma
3
Wilms Tumor
2
Sarcoma, Ewing
2
Sarcoma
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Glioma
2
Ependymoma
2
Xanthogranuloma, Juvenile
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Pheochromocytoma
1
Melanoma
1
Histiocytic Sarcoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Central Nervous System Neoplasms
1
Interventions
Paclitaxel
7
Cyclophosphamide
6
Doxorubicin
5
pembrolizumab
3
Trastuzumab
3
Taxes
3
Specimen Handling
3
Carboplatin
3
pertuzumab
2
eribulin
2
Radiotherapy
2
Epirubicin
2
Docetaxel
2
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
ruxolitinib
1
pegfilgrastim
1
onvansertib
1
olaparib
1
neratinib
1
durvalumab
1
cobimetinib
1
atezolizumab
1
X-Rays
1
Therapeutics
1
Tamoxifen
1
Surgical Procedures, Operative
1
Radiation
1
Peripheral Blood Stem Cell Transplantation
1
Panitumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Inflammatory Breast Neoplasms
×
tipifarnib
×
1 year
×
Clear all
No trials found.